PT Diastika Biotekindo Tbk (ISX:CHEK) Return-on-Tangible-Equity: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PT Diastika Biotekindo Tbk Return-on-Tangible-Equity?

PT Diastika Biotekindo Tbk ISX:CHEK +3.88% Return-on-Tangible-Equity is 0.00% as of . 20. The stock has 1 warning sign investors should review. Among 759 Medical Devices & Instruments companies, PT Diastika Biotekindo Tbk ranks worse than 131752.17% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. PT Diastika Biotekindo Tbk's annualized net income for the quarter that ended in . 20 was Rp Mil. PT Diastika Biotekindo Tbk's average shareholder tangible equity for the quarter that ended in . 20 was Rp Mil. Therefore, PT Diastika Biotekindo Tbk's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 was %.

The historical rank and industry rank for PT Diastika Biotekindo Tbk's Return-on-Tangible-Equity or its related term are showing as below:

ISX:CHEK's Return-on-Tangible-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.02
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

PT Diastika Biotekindo Tbk  (ISX:CHEK) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

PT Diastika Biotekindo Tbk Return-on-Tangible-Equity Related Terms

PT Diastika Biotekindo Tbk Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for PT Diastika Biotekindo Tbk's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Diastika Biotekindo Tbk Return-on-Tangible-Equity Chart

PT Diastika Biotekindo Tbk Annual Data
Trend
Return-on-Tangible-Equity

PT Diastika Biotekindo Tbk Semi-Annual Data
Return-on-Tangible-Equity

ISX:CHEK vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison

For the Medical Devices subindustry, PT Diastika Biotekindo Tbk's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PT Diastika Biotekindo Tbk Return-on-Tangible-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PT Diastika Biotekindo Tbk's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where PT Diastika Biotekindo Tbk's Return-on-Tangible-Equity falls into.


PT Diastika Biotekindo Tbk Return-on-Tangible-Equity Calculation

PT Diastika Biotekindo Tbk's annualized Return-on-Tangible-Equity for the fiscal year that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( (+ )/ )
=/
= %

PT Diastika Biotekindo Tbk's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (. 20) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
PT Diastika Biotekindo Tbk (ISX:CHEK) has a Return-on-Tangible-Equity of 0.00% as of . 20. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PT Diastika Biotekindo Tbk and its competitors. According to the industry distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 759 companies in the Medical Devices & Instruments industry.
Is PT Diastika Biotekindo Tbk's Return-on-Tangible-Equity too high?
PT Diastika Biotekindo Tbk's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 759 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does PT Diastika Biotekindo Tbk's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 759 companies for Return-on-Tangible-Equity. This places PT Diastika Biotekindo Tbk in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.02, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PT Diastika Biotekindo Tbk and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Diastika Biotekindo Tbk's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Diastika Biotekindo Tbk stock overvalued right now?
PT Diastika Biotekindo Tbk (ISX:CHEK) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For PT Diastika Biotekindo Tbk (ISX:CHEK), the current Return-on-Tangible-Equity is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PT Diastika Biotekindo Tbk Business Description

Address Jalan Rawagelam V, Kawasan Industri Pulogadung, Block L, No. Kav 11-13, Gedung Etana Lantai 3, Desa/Kelurahan Jatinegara, Kec. Cakung, Kota Adm. Jakarta Timur, Jakarta, IDN, 13930
PT Diastika Biotekindo Tbk is engaged in providing medical and laboratory equipment solutions in Indonesia. It is engaged in the wholesale trading of laboratory equipment, pharmaceutical products, and medical devices for human use. The company is also involved in wholesale trading of radioactive substances and ionizing radiation generators, and undertakes activities related to the testing and/or calibration of medical devices, as well as the inspection of healthcare facilities and infrastructure. Its product offerings mainly include devices like hematology analyzer, pipette, hemoglobin testing system, etc. The company's operating segments are: Diagnostics Group, which generates the maximum revenue, and Life Sciences Group. Geographically, all of its revenue is derived from Indonesia.